Results 21 to 30 of about 30,408 (190)

In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus

, 2022
Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates using different media and
Akdoğan Kittana, Fatma Nur, Schulthess, Bettina, Hömke, Rico, Sander, Peter   +3 more
core   +2 more sources

Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Tuberculosis (TB) treatment requires long‐term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open‐source, modular framework connecting high‐throughput PBPK (HT‐PBPK) simulations, mechanistic PBPK models, pharmacodynamic endpoints, and safety predictions for anti ...
Siccardi M, Nauwelaerts N, Lesage R, Lefaudeux D, Baier V, Karamitsou V, Demeester C, Huang M, Kulesza A, Schaller S.   +9 more
europepmc   +2 more sources

Emergence of bedaquiline resistance in a high tuberculosis burden country

, 2021
Rationale: Bedaquiline has been classified as a group A drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally emerging resistance threatens the effectivity of novel MDR-TB treatment ...
Barilar, Ivan,, Crudu, Valeriu,, Utpatel, Christian, Andres, Sönke,, Maurer, Florian P., Crudu, Valeriu, Chesov, Dumitru, Heyckendorf, Jan,, Reimann, Maja, Lange, Christoph, Niemann, Stefan,, Lange, Christoph,, Donica, Ana, Maurer, Florian P.,, Chesov, Dumitru,, Reimann, Maja,, Donica, Ana,, Chesov, Elena, Utpatel, Christian,, Andres, Sönke, Barilar, Ivan, Niemann, Stefan, Merker, Matthias, Heyckendorf, Jan, Merker, Matthias,, Chesov, Elena,, Matthias Merker, Valeriu Crudu, Christian Utpatel, Christoph Lange, Dumitru Chesov, Stefan Niemann, Jan Heyckendorf, Ivan Barilar, Sönke Andres, Ana Donica, Maja Reimann, Florian P. Maurer, Elena Chesov   +38 more
core   +1 more source

Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase

Frontiers in Immunology, 2021
Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms.
Gregory R. Tintinger, Annette J. Theron, Helen C. Steel, Moloko C. Cholo, Jan G. Nel, Jan G. Nel, Charles Feldman, Ronald Anderson   +7 more
doaj   +1 more source

Evaluation of physicochemical stability and degradation kinetics of bedaquiline in hydrolytic solutions of different pH

Future Journal of Pharmaceutical Sciences, 2021
Background Tuberculosis is an infection that has high mortality rate in human as well as in animals if it remains unattained for long time. Scientists are always desirous to discover new molecules against Mycobacterium tuberculosis; one of them is ...
S. J. Rajput, P. J. Vanavi
doaj   +1 more source

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, Hyesung Lee, In-Sun Oh, Han Eol Jeong, Sungho Bea, Seung Hun Jang, Hyunjin Son, Ju-Young Shin   +7 more
doaj   +1 more source

Prolonged use of bedaquiline in the treatment for MDR-TB in a child

IDCases, 2021
Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months.
Marina F. Gubkina, Julia Yu. Khokhlova, Natalia V. Yukhimenko, Irina Yu. Petrakova   +3 more
doaj   +1 more source

Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.

PLoS Medicine, 2016
BackgroundNew drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established.
Amber Kunkel, Frank G Cobelens, Ted Cohen   +2 more
doaj   +1 more source

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study

Microbiology Spectrum, 2023
With the application of bedaquiline (Bdq), the success rate of multidrug-resistant tuberculosis (MDR-TB) treatment has been significantly improved; however, the cardiac safety of the patients during treatment cannot be ignored. Hence, this study compared
Rong Li, Jin-Bao Ma, Hong Yang, Han Yang, Xin-Jun Yang, Yan-Qin Wu, Fei Ren   +6 more
doaj   +1 more source

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. [PDF]

, 2019
There are limited data on combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable.We prospectively followed up 122 South African patients (
Esmail, Aliasgar, Limberis, Jason, Olayanju, Olatunde, Dheda, Keertan   +3 more
core   +1 more source